JP7282736B2 - カプサイシンを使用した疼痛の治療のための方法及び組成物 - Google Patents

カプサイシンを使用した疼痛の治療のための方法及び組成物 Download PDF

Info

Publication number
JP7282736B2
JP7282736B2 JP2020502343A JP2020502343A JP7282736B2 JP 7282736 B2 JP7282736 B2 JP 7282736B2 JP 2020502343 A JP2020502343 A JP 2020502343A JP 2020502343 A JP2020502343 A JP 2020502343A JP 7282736 B2 JP7282736 B2 JP 7282736B2
Authority
JP
Japan
Prior art keywords
joint
certain embodiments
patient
skin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527574A (ja
JP2020527574A5 (https=
Inventor
ジェイムズ・エヌ・キャンベル
ピーター・ディ・ハンソン
ゲイリー・エフ・ムッソ
ドレイゼン・オストビック
ランドール・スティーブンズ
Original Assignee
セントレクシオン セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントレクシオン セラピューティクス コーポレイション filed Critical セントレクシオン セラピューティクス コーポレイション
Publication of JP2020527574A publication Critical patent/JP2020527574A/ja
Publication of JP2020527574A5 publication Critical patent/JP2020527574A5/ja
Priority to JP2023081213A priority Critical patent/JP7738031B2/ja
Application granted granted Critical
Publication of JP7282736B2 publication Critical patent/JP7282736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/10—Cooling bags, e.g. ice-bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001—Body part
    • A61F2007/0039—Leg or parts thereof
    • A61F2007/0042—Knee

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
JP2020502343A 2017-07-20 2018-07-20 カプサイシンを使用した疼痛の治療のための方法及び組成物 Active JP7282736B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081213A JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535003P 2017-07-20 2017-07-20
US62/535,003 2017-07-20
PCT/US2018/043094 WO2019018769A1 (en) 2017-07-20 2018-07-20 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081213A Division JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020527574A JP2020527574A (ja) 2020-09-10
JP2020527574A5 JP2020527574A5 (https=) 2021-08-26
JP7282736B2 true JP7282736B2 (ja) 2023-05-29

Family

ID=65016186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502343A Active JP7282736B2 (ja) 2017-07-20 2018-07-20 カプサイシンを使用した疼痛の治療のための方法及び組成物
JP2023081213A Active JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081213A Active JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Country Status (11)

Country Link
US (4) US20200206166A1 (https=)
EP (1) EP3654961B1 (https=)
JP (2) JP7282736B2 (https=)
CN (1) CN111201015A (https=)
AU (1) AU2018302342B2 (https=)
BR (1) BR112020000989A2 (https=)
CA (1) CA3069540A1 (https=)
ES (1) ES3018268T3 (https=)
IL (1) IL272036B2 (https=)
MX (1) MX2020000488A (https=)
WO (1) WO2019018769A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023116457A (ja) * 2017-07-20 2023-08-22 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3840739B1 (en) * 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
CN114028540B (zh) * 2021-11-26 2023-10-17 海南鑫开源医药科技有限公司 一种具有镇痛作用的组合物、微针贴片及其制备方法以及应用
CN115006379B (zh) * 2021-12-28 2023-12-15 南京清普生物科技有限公司 一种trpv1激动剂原位膜剂组合物，及其制备方法和用途
KR20250075704A (ko) * 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536998A (ja) 2012-11-12 2015-12-24 エイピーアイ・ジェネシス，エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法
JP2016540830A (ja) 2013-11-12 2016-12-28 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 水性カプサイシノイド配合物ならびに製造法および使用法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
EP0646372B1 (de) 1993-09-30 1999-03-31 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
AU5460598A (en) 1996-11-15 1998-06-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
ATE481970T1 (de) 1997-03-13 2010-10-15 James N Campbell Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
WO1998053825A1 (en) 1997-05-27 1998-12-03 Algos Pharmaceutical Corporation Analgesic drug composition containing a capsaicinoid and potentiator therefor
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
CA2493041C (en) 2002-07-19 2011-08-16 Dominik Meyer Injectable pharmaceutical composition for treating post-operative joint pain comprising an amide local anesthetic
MXPA05006670A (es) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
US20040161481A1 (en) 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
ES2535045T3 (es) 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2005309586A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
EP1830836B1 (de) 2004-12-22 2010-11-24 Mestex AG Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
JP5775246B2 (ja) 2004-12-28 2015-09-09 メステックス アクチェンゲゼルシャフトＭｅｓｔｅｘ Ａｇ 関節痛を治療する薬剤を生成するためのレシニフェラトキシン（ｒｔｘ）の使用方法および前記薬剤を適用する方法
CA2594203C (en) 2004-12-28 2014-04-29 Mestex Ag Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pain and method for applying said agent
US20060222690A1 (en) * 2005-03-30 2006-10-05 Bley Keith R Low-concentration capsaicin patch and methods for treating neuropathic pain
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
JP2013523274A (ja) * 2010-03-30 2013-06-17 ザ チルドレンズ リサーチ インスティテュート ヒトの痛覚の測定の装置及び方法
WO2013036961A1 (en) * 2011-09-09 2013-03-14 Api Genesis Llc A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
US9566187B2 (en) 2012-03-13 2017-02-14 Breg, Inc. Cold therapy systems and methods
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
EP2838536B1 (en) 2012-04-18 2017-08-09 Mallinckrodt LLC Immediate release pharmaceutical compositions with abuse deterrent properties
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CA2880855A1 (en) 2012-08-03 2014-02-06 Mestex Ag Resiniferatoxin solution
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
ES2838756T3 (es) 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
EP3131541A4 (en) 2014-04-14 2018-02-14 Flex Pharma, Inc. Ion channel activators and methods of use
CA2945818C (en) 2014-04-15 2022-05-03 Vizuri Health Sciences Llc Topical compositions comprising a capsaicinoid for pain relief, manufacture and use
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
US20170239198A1 (en) 2014-08-19 2017-08-24 Mandishora Israel Muzari Capsaicinoids and uses thereof as medicaments
WO2016077749A1 (en) 2014-11-13 2016-05-19 Centrexion Therapeutics Corporation Capsaicinoids for use in treating acral lick granuloma
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN107847451A (zh) 2015-02-02 2018-03-27 英仕柏集团有限责任公司 稳定的富马酸二烷基酯组合物
CA2987517A1 (en) 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
WO2017087803A1 (en) 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
WO2017127628A1 (en) * 2016-01-22 2017-07-27 Centrexion Therapeutics Corporation Capsaicn sequential dosing method for treatment of morton's neuroma pain
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
NZ752750A (en) 2016-11-02 2023-05-26 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
ES3018268T3 (en) * 2017-07-20 2025-05-14 Centrexion Therapeutics Corp Compositions and their use for treatment of pain using capsaicin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536998A (ja) 2012-11-12 2015-12-24 エイピーアイ・ジェネシス，エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法
JP2016540830A (ja) 2013-11-12 2016-12-28 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 水性カプサイシノイド配合物ならびに製造法および使用法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Neurophysiology，1991年， 66(1)，pp.190-211

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023116457A (ja) * 2017-07-20 2023-08-22 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物
JP7738031B2 (ja) 2017-07-20 2025-09-11 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物

Also Published As

Publication number Publication date
AU2018302342B2 (en) 2024-08-08
JP2020527574A (ja) 2020-09-10
IL272036B2 (en) 2025-01-01
AU2018302342A1 (en) 2020-02-06
EP3654961A4 (en) 2021-04-21
IL272036A (en) 2020-03-31
CA3069540A1 (en) 2019-01-24
EP3654961A1 (en) 2020-05-27
BR112020000989A2 (pt) 2020-07-14
EP3654961C0 (en) 2025-01-08
WO2019018769A1 (en) 2019-01-24
US20200206166A1 (en) 2020-07-02
US20210299072A1 (en) 2021-09-30
CN111201015A (zh) 2020-05-26
US11026903B2 (en) 2021-06-08
US20250312298A1 (en) 2025-10-09
US12201594B2 (en) 2025-01-21
JP2023116457A (ja) 2023-08-22
MX2020000488A (es) 2020-10-28
ES3018268T3 (en) 2025-05-14
JP7738031B2 (ja) 2025-09-11
US20200360314A1 (en) 2020-11-19
IL272036B1 (en) 2024-09-01
EP3654961B1 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
JP7738031B2 (ja) カプサイシンを使用した疼痛の治療のための方法及び組成物
CN104968330A (zh) 用于治疗剧痛的组合物及方法
Daneshkazemi et al. The efficacy of eutectic mixture of local anesthetics as a topical anesthetic agent used for dental procedures: A brief review
JP7100635B2 (ja) 安定な水性カプサイシン注射製剤およびその医学的使用
US20200297670A1 (en) Capsaicin Sequential Dosing Method for Treatment of Morton's Neuroma Pain
US20250241879A1 (en) Capsaicin sequential dosing method for treatment of knee joint pain
Webster et al. Review of intra‐articular local anaesthetic administration in horses: Clinical indications, cytotoxicity, and outcomes
Wong et al. Comparison of the Effect of Two Different Doses of 0.75% Glucose‐Free Ropivacaine for Spinal Anesthesia for Lower Limb and Lower Abdominal Surgery
HK40031064B (en) Compositions and their use for treatment of pain using capsaicin
HK40031064A (en) Compositions and their use for treatment of pain using capsaicin
Jin et al. Effects of Low-Dose Dexamethasone Regimens on Early Clinical Outcomes After Unicompartmental Knee Arthroplasty: A Retrospective Cohort Study
Mallika et al. ROLE OF DEXMEDETOMIDINE AND CLONIDINE AS ADJUVANTS WITH ROPIVACAINE IN EPIDURAL ANAESTHESIA-A COMPARATIVE STUDY
Hassan et al. Pharmacodynamic evaluation of dexmedetomidine as an additive drug to bupivacaine in ultrasound-guided interscalene brachial plexus block.
Mosimann et al. Usefulness of intra-articular bupivacain and lidocain adjunction in MR or CT arthrography: A prospective study in 148 patients
Shehab et al. Therapeutic efficacy of a preoperative epidural single shot of dexamethasone/levobupivacaine for postoperative analgesia (a placebo-controlled comparative study against epidural neostigmine/levobupivacaine)
Gritsenko et al. Postoperative Blocks That Afford Long-Lasting Pain Relief

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230517

R150 Certificate of patent or registration of utility model

Ref document number: 7282736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150